-

Shareholder Alert: Robbins LLP Announces Fluor Corporation (FLR) Sued for Misleading Shareholders

SAN DIEGO & IRVING, Texas--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Fluor Corporation (NYSE: FLR) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between November 2, 2017 and February 14, 2020. Fluor provides engineering, procurement, construction, fabrication and modularization, operation, maintenance and asset integrity, and project management services.

If you suffered a loss as a result of Fluor's misconduct, click here.

Fluor Corporation (FLR) Accused of Improperly Inflating Revenue

According to the complaint, throughout the relevant period, Fluor would improperly recognize revenue on its projects by routinely submitting "change forms" to its clients requesting additional funds to cover its costs overruns from "unforeseen circumstances" and booking this additional revenue when it determined it was "likely" the client would accept the change order. These tactics to inflate revenue were thwarted on August 1, 2019, when Fluor revealed the Company would be taking a $714 million pre-tax charge on approximately 16 different projects in addition to a $233 million charge on a project Fluor sub-contracted. Then, on February 18, 2020, Fluor revealed that it would not be able to complete and file its Form 10-K on time due to SEC and internal investigations of Fluor's past accounting and financial reporting. On this news, the stock fell to $14.79 per share, representing an almost 75% decline from its class period high of $58.16 per share.

Fluor Corporation (FLR) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:FLR

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom